WilmerHale Advises Thermo Fisher Scientific in $1.14B Sale of Anatomical Pathology Business

WilmerHale Advises Thermo Fisher Scientific in $1.14B Sale of Anatomical Pathology Business

Client News

Related Solutions

WilmerHale’s corporate lawyers have a long history of experience with cross-border deals involving mergers and acquisitions, public offerings and capital markets, venture capital, joint ventures and other transactions.
Lawyers with deep and broad experience counseling clients in every industry on the design, implementation, and interpretation of executive compensation arrangements and on general compensation and benefits issues.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.
A deep and diverse practice focused on maximizing tax efficiencies and minimizing tax risks for clients nationally and internationally.

On January 28, 2019, Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it signed a definitive agreement to sell its Anatomical Pathology business to PHC Holdings Corporation, a global innovator in healthcare solutions, for approximately $1.14 billion in cash. Thermo Fisher anticipates closing the transaction in the second quarter of 2019, subject to customary closing conditions and applicable regulatory approvals. 

The WilmerHale team representing Thermo Fisher on the deal was led by Hal Leibowitz, Joe Conahan and Andrew Langworthy and included Robert Burke, Ciara Baker, John Sigel, Justin Ochs, Amy Null, Scott Kilgore, Ashwin Gokhale, Christian Crones, Lester Ross and Jasmine Haddad. 

Read the press release announcing the signing of this agreement.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel